Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 4, 2000, Pages 1492-1497

  Ravn, Pernille ^a   Weiss, Stuart R ^b   Rodriguez Portales, Jose A ^c   McClung, Michael R ^d   Wasnich, Richard D ^e   Gilchrist, Nigel L ^f   Sambrook, Philip ^g   Fogelman, Ignac ^h   Krupa, David ⁱ   Yates, A John ⁱ   Daifotis, Anastasia ⁱ   Fuleihan, Ghada El Hajj ^j  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b San Diego Endocrine and Medical Clinic   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d OREGON OSTEOPOROSIS CENTER   (United States)

^e Hawaii Osteoporosis Center   (United States)

^f PRINCESS MARGARET HOSPITAL   (New Zealand)

^g UNIVERSITY OF SYDNEY   (Australia)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PLACEBO;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FEMUR; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; LONG TERM CARE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE;

ADULT; ALENDRONATE; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PLACEBOS; POSTMENOPAUSE;

EID: 17744399512     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.4.1492     Document Type: Article

References (25)

1. Bisphosphonates: Mechanisms of action
2. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
3. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
4. Alendronate treatment of the postmenopausal osteoporoticwoman: Effect of multiple dosages on bone mass and bone remodeling
5. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
6. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
7. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind randomized, controlled trial
8. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
9. Studies of the oral bioavailability of alendronate
10. Bisphosphonate effects and the bone remodeling transient
11. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
12. Bone composition of the distal forearm
13. Bone densitometry: A new highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment
14. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals
15. 3H-alendronate and 3H-etidronate in rat and mouse bones
16. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
17. Sustained response to intravenous alendronate in postmenopausal osteoporosis
18. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
19. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate
20. Calcium supplementation, and bone loss: A review of controlled trials
21. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
22. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up
23. Alendronate and estrogen-progestin prevent bone loss: Four-year results from the Early Postmenopausal Intervention Cohort Study. A randomized, controlled trial
24. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women
25. Dose-response relationships for alendronate treatment in osteoporotic elderly women